Nivolumab plus Ipilimumab versus Lenvatinib or Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: CheckMate 9DW Japanese Subgroup Analysis

Masatoshi Kudo, Atsushi Hiraoka, Kazushi Numata, Tatsuya Yamashita, Masayuki Kurosaki, Tadashi Namisaki, Shuhei Hige, Yoshito Itoh, Satoshi Mochida, Tetsuya Hosaka, Norio Akuta, Tomokazu Kawaoka, Takuya Genda, Satoshi Kobayashi, Sawako Uchida-Kobayashi, Yuting Lu, Tatsuya Ogata, Maria Jesus Jimenez Exposito, Masafumi Ikeda

Open source

DOI: 10.1159/000548300
Published: 2025-09-08
Container: Liver Cancer
Publisher: S. Karger AG
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1159/000548300,
  title = {Nivolumab plus Ipilimumab versus Lenvatinib or Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: CheckMate 9DW Japanese Subgroup Analysis},
  author = {Masatoshi Kudo and Atsushi Hiraoka and Kazushi Numata and Tatsuya Yamashita and Masayuki Kurosaki and Tadashi Namisaki and Shuhei Hige and Yoshito Itoh and Satoshi Mochida and Tetsuya Hosaka and Norio Akuta and Tomokazu Kawaoka and Takuya Genda and Satoshi Kobayashi and Sawako Uchida-Kobayashi and Yuting Lu and Tatsuya Ogata and Maria Jesus Jimenez Exposito and Masafumi Ikeda},
  year = {2025},
  journal = {Liver Cancer},
  doi = {10.1159/000548300},
  url = {https://doi.org/10.1159/000548300}
}

RIS

TY  - JOUR
TI  - Nivolumab plus Ipilimumab versus Lenvatinib or Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: CheckMate 9DW Japanese Subgroup Analysis
AU  - Masatoshi Kudo
AU  - Atsushi Hiraoka
AU  - Kazushi Numata
AU  - Tatsuya Yamashita
AU  - Masayuki Kurosaki
AU  - Tadashi Namisaki
AU  - Shuhei Hige
AU  - Yoshito Itoh
AU  - Satoshi Mochida
AU  - Tetsuya Hosaka
AU  - Norio Akuta
AU  - Tomokazu Kawaoka
AU  - Takuya Genda
AU  - Satoshi Kobayashi
AU  - Sawako Uchida-Kobayashi
AU  - Yuting Lu
AU  - Tatsuya Ogata
AU  - Maria Jesus Jimenez Exposito
AU  - Masafumi Ikeda
PY  - 2025
JO  - Liver Cancer
DO  - 10.1159/000548300
UR  - https://doi.org/10.1159/000548300
ER  -

APA

Kudo, M., Hiraoka, A., Numata, K., Yamashita, T., Kurosaki, M., Namisaki, T., Hige, S., Itoh, Y., Mochida, S., Hosaka, T., Akuta, N., Kawaoka, T., Genda, T., Kobayashi, S., Uchida-Kobayashi, S., Lu, Y., Ogata, T., Exposito, M. J. J., & Ikeda, M. (2025). Nivolumab plus Ipilimumab versus Lenvatinib or Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: CheckMate 9DW Japanese Subgroup Analysis. Liver Cancer. https://doi.org/10.1159/000548300

Source records

crossref · retrieved 2026-09-26T12:24:58.387Z